Clinical research and studies demonstrate Gondola AMPS therapy's effectiveness for people with neurological disease to move better and live better. The CHF 500’000 Tech Growth loan from the Fondation pour l'Innovation Technologique (FIT) supports Gondola Medical Technologies to scale their clinical research capabilities further.
Francesco Cecchini, CEO states: "Building a capable team - I like to use the word Gondola Dream Team - is one of the most challenging and also rewarding tasks. Having a solid clinical team that shows that we are backed by science was and is decisive for us as a scale-up therapeutic company".
Backed by science
Clinical studies show the benefits of Gondola AMPS therapy for Parkinson's disease patients. It is the ambition to validate the treatment also for other neurological disorders such as stroke. Besides international collaborations, Gondola Medical Technologies entertains an active exchange with CHUV in Lausanne to explore future joint research activities.
AMPS therapy: walking therapy for neurological disorders
The Gondola AMPS therapy works with mechanical pressure pulses applied in two specific areas of both feet, the head of the big toe and the first metatarsal joint. It is a two-minute therapy with instant-on results that is documented in 12 scientific publications with more than 230 Parkinson's disease patients. Gondola AMPS treatment's documented benefits provide significant improvements in walking abilities for speed, stride length, gait variability, and turning. Beneficial effects are apparent immediately after a single AMPS treatment and can remain on average two to four days. Continual use allows to maintain benefits long-term.
(Press release)
Please login or sign up to comment.
Commenting guidelines